## CORRECTION Open Access



## Correction: Dual antibody-aided mesoporous nanoreactor for H<sub>2</sub>O<sub>2</sub> self-supplying chemodynamic therapy and checkpoint blockade immunotherapy in triple-negative breast cancer

Ying-Tzu Chen<sup>1,2</sup>, Ying-Xiang Luo<sup>3</sup>, Shih-Hsuan Chan<sup>4,5,6</sup>, Wen-Yi Chiu<sup>3,7\*†</sup> and Hung-Wei Yang<sup>1,8\*†</sup>

Correction: Chen et al. Journal of Nanobiotechnology (2023) 21:385

https://doi.org/10.1186/s12951-023-02154-0

In this article the statement in the Funding information section was incorrectly given as 'This research was financially backed by the National Science and

<sup>†</sup>Wen-Yi Chiu and Hung-Wei Yang jointly supervised this work.

The online version of the original article can be found at https://doi.org/10.1186/s12951-023-02154-0.

\*Correspondence:

Wen-Yi Chiu

hanrogyi@gmail.com

Hung-Wei Yang

howardyang@gs.ncku.edu.tw

<sup>1</sup>Department of Biomedical Engineering, National Cheng Kung University, Tainan 70101, Taiwan

<sup>2</sup>Department of Neurosurgery, Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou 33305, Taoyuan, Taiwan

<sup>3</sup>Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan

<sup>4</sup>School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan

<sup>5</sup>Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 40402, Taiwan

<sup>6</sup>Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan

<sup>7</sup>Department of Family Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan

<sup>8</sup>Medical Device Innovation Center, National Cheng Kung University, Tainan 70101, Taiwan Technology Council (NSTC110-2628-B-110-004, NSTC111-2628-B-006-023, NSTC112-2628-B-006-015) and National Health Research Institutes (NHRI-EX112-11226EI), Taiwan' and should have read

'This work was financially supported by the National Science and Technology Council (NSTC111- 2628-B-006-023 and NSTC112-2628-B-006-015), National Health Research Institutes (NHRI-EX112- 11226EI), and Kaohsiung Armed Forces General Hospital (KAFGH\_D\_110025), Taiwan'.

The original article [1] has been corrected.

Published online: 21 December 2023

## References

 Chen YT, Luo YX, Chan SH, et al. Dual antibody-aided mesoporous nanoreactor for H<sub>2</sub>O<sub>2</sub> self-supplying chemodynamic therapy and checkpoint blockade immunotherapy in triple-negative breast cancer. J Nanobiotechnol. 2023;21(1):385.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.